{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,31]],"date-time":"2025-12-31T10:49:05Z","timestamp":1767178145763,"version":"build-2238731810"},"reference-count":28,"publisher":"Public Library of Science (PLoS)","issue":"2","license":[{"start":{"date-parts":[[2014,2,28]],"date-time":"2014-02-28T00:00:00Z","timestamp":1393545600000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS ONE"],"DOI":"10.1371\/journal.pone.0090009","type":"journal-article","created":{"date-parts":[[2014,2,28]],"date-time":"2014-02-28T16:53:35Z","timestamp":1393606415000},"page":"e90009","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":11,"title":["Circulating Ang-2 mRNA Expression Levels: Looking Ahead to a New Prognostic Factor for NSCLC"],"prefix":"10.1371","volume":"9","author":[{"given":"Ana L.","family":"Coelho","sequence":"first","affiliation":[]},{"given":"Ant\u00f3nio","family":"Ara\u00fajo","sequence":"additional","affiliation":[]},{"given":"M\u00f3nica","family":"Gomes","sequence":"additional","affiliation":[]},{"given":"Raquel","family":"Catarino","sequence":"additional","affiliation":[]},{"given":"Agostinho","family":"Marques","sequence":"additional","affiliation":[]},{"given":"Rui","family":"Medeiros","sequence":"additional","affiliation":[]}],"member":"340","published-online":{"date-parts":[[2014,2,28]]},"reference":[{"key":"ref1","doi-asserted-by":"crossref","first-page":"720","DOI":"10.1016\/S0140-6736(13)61715-8","article-title":"Genetics and biomarkers in personalisation of lung cancer treatment","volume":"382","author":"R Rosell","year":"2013","journal-title":"Lancet"},{"key":"ref2","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1016\/S0140-6736(13)61502-0","article-title":"Management of non-small-cell lung cancer: recent developments","volume":"382","author":"M Reck","year":"2013","journal-title":"Lancet"},{"key":"ref3","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1038\/35025220","article-title":"Angiogenesis in cancer and other diseases","volume":"407","author":"P Carmeliet","year":"2000","journal-title":"Nature"},{"key":"ref4","doi-asserted-by":"crossref","first-page":"2159","DOI":"10.2353\/ajpath.2009.090391","article-title":"Contrasting actions of selective inhibitors of angiopoietin-1 and angiopoietin-2 on the normalization of tumor blood vessels","volume":"175","author":"BL Falcon","year":"2009","journal-title":"Am J Pathol"},{"key":"ref5","doi-asserted-by":"crossref","first-page":"1649","DOI":"10.1158\/0008-5472.CAN-12-4697","article-title":"Angiopoietin-2: an attractive target for improved antiangiogenic tumor therapy","volume":"73","author":"D Gerald","year":"2013","journal-title":"Cancer Res"},{"key":"ref6","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1016\/j.canlet.2012.08.018","article-title":"Angiopoietins in angiogenesis","volume":"328","author":"E Fagiani","year":"2013","journal-title":"Cancer Lett"},{"key":"ref7","doi-asserted-by":"crossref","first-page":"1324","DOI":"10.1158\/0008-5472.CAN-08-3030","article-title":"Host-derived angiopoietin-2 affects early stages of tumor development and vessel maturation but is dispensable for later stages of tumor growth","volume":"69","author":"P Nasarre","year":"2009","journal-title":"Cancer Res"},{"key":"ref8","doi-asserted-by":"crossref","first-page":"1991","DOI":"10.1172\/JCI58832","article-title":"Angiopoietin-2 differentially regulates angiogenesis through TIE2 and integrin signaling","volume":"122","author":"M Felcht","year":"2012","journal-title":"J Clin Invest"},{"key":"ref9","doi-asserted-by":"crossref","unstructured":"Kienast Y, Klein C, Scheuer W, Raemsch R, Lorenzon E, <etal>et al<\/etal>.. (2013) Ang-2-VEGF-A CrossMab, a novel bispecific human IgG1 antibody blocking VEGF-A and Ang-2 functions simultaneously, mediates potent anti-tumor, anti-angiogenic, and anti-metastatic efficacy. Clin Cancer Res.","DOI":"10.1158\/1078-0432.CCR-13-0081"},{"key":"ref10","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1038\/nrm2639","article-title":"Control of vascular morphogenesis and homeostasis through the angiopoietin-Tie system","volume":"10","author":"HG Augustin","year":"2009","journal-title":"Nat Rev Mol Cell Biol"},{"key":"ref11","doi-asserted-by":"crossref","first-page":"e19773","DOI":"10.1371\/journal.pone.0019773","article-title":"Prognostic impacts of angiopoietins in NSCLC tumor cells and stroma: VEGF-A impact is strongly associated with Ang-2","volume":"6","author":"S Andersen","year":"2011","journal-title":"PLoS One"},{"key":"ref12","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1080\/07357900802672704","article-title":"Serum levels of angiopoietin-1, angiopoietin-2, and their receptor tie-2 in patients with nonsmall cell lung cancer during chemotherapy","volume":"27","author":"W Naumnik","year":"2009","journal-title":"Cancer Invest"},{"key":"ref13","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1007\/978-94-007-6627-3_46","article-title":"Angiogenic axis angiopoietin-1 and angiopoietin-2\/Tie-2 in non-small cell lung cancer: a bronchoalveolar lavage and serum study","volume":"788","author":"W Naumnik","year":"2013","journal-title":"Adv Exp Med Biol"},{"key":"ref14","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1378\/chest.06-2915","article-title":"Serum angiopoietin-2 as a clinical marker for lung cancer","volume":"132","author":"JH Park","year":"2007","journal-title":"Chest"},{"key":"ref15","first-page":"849","article-title":"Overexpression of Ang-2 mRNA in non-small cell lung cancer: association with angiogenesis and poor prognosis","volume":"12","author":"I Takanami","year":"2004","journal-title":"Oncol Rep"},{"key":"ref16","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1097\/00000421-198212000-00014","article-title":"Toxicity and response criteria of the Eastern Cooperative Oncology Group","volume":"5","author":"MM Oken","year":"1982","journal-title":"Am J Clin Oncol"},{"key":"ref17","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1006\/meth.2001.1262","article-title":"Analysis of Relative Gene Expression Data Using Real-Time Quantitative PCR and the 2<sup>\u2212\u0394\u0394C<\/sup>T Method","volume":"25","author":"KJ Livak","year":"2001","journal-title":"Methods"},{"key":"ref18","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1634\/theoncologist.12-2-201","article-title":"Genetic polymorphisms of the epidermal growth factor and related receptor in non-small cell lung cancer\u2014a review of the literature","volume":"12","author":"A Araujo","year":"2007","journal-title":"Oncologist"},{"key":"ref19","doi-asserted-by":"crossref","first-page":"1727","DOI":"10.1016\/S0140-6736(10)62101-0","article-title":"Non-small-cell lung cancer","volume":"378","author":"P Goldstraw","year":"2011","journal-title":"Lancet"},{"key":"ref20","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1186\/1756-9966-30-115","article-title":"Adjuvant chemotherapy for resected non-small-cell lung cancer: future perspectives for clinical research","volume":"30","author":"M Bonomi","year":"2011","journal-title":"J Exp Clin Cancer Res"},{"key":"ref21","doi-asserted-by":"crossref","first-page":"1039","DOI":"10.1200\/JCO.2012.45.3753","article-title":"Genotyping and genomic profiling of non-small-cell lung cancer: implications for current and future therapies","volume":"31","author":"T Li","year":"2013","journal-title":"J Clin Oncol"},{"key":"ref22","doi-asserted-by":"crossref","first-page":"1693","DOI":"10.1056\/NEJMoa1006448","article-title":"Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer","volume":"363","author":"EL Kwak","year":"2010","journal-title":"N Engl J Med"},{"key":"ref23","doi-asserted-by":"crossref","first-page":"1235","DOI":"10.6004\/jnccn.2013.0146","article-title":"Targeting angiogenesis in advanced non-small cell lung cancer","volume":"11","author":"PE Lammers","year":"2013","journal-title":"J Natl Compr Canc Netw"},{"key":"ref24","doi-asserted-by":"crossref","first-page":"929","DOI":"10.1158\/1078-0432.CCR-12-2535","article-title":"Predictive impact of circulating vascular endothelial growth factor in four phase III trials evaluating bevacizumab","volume":"19","author":"PS Hegde","year":"2013","journal-title":"Clin Cancer Res"},{"key":"ref25","doi-asserted-by":"crossref","first-page":"e54923","DOI":"10.1371\/journal.pone.0054923","article-title":"A novel angiopoietin-2 selective fully human antibody with potent anti-tumoral and anti-angiogenic efficacy and superior side effect profile compared to Pan-Angiopoietin-1\/-2 inhibitors","volume":"8","author":"M Thomas","year":"2013","journal-title":"PLoS One"},{"key":"ref26","volume":"29","unstructured":"KP P, NG C, A P, L A, AS L, <etal>et al<\/etal>.. (2011) A phase I first-in-human study of REGN910, a fully human and selective angiopoietin-2 monoclonal antibody, in patients with advanced solid tumor malignancies. Journal of Clinical Oncology <volume>29<\/volume>.."},{"key":"ref27","doi-asserted-by":"crossref","first-page":"1891","DOI":"10.1111\/j.1476-5381.2011.01677.x","article-title":"A novel angiopoietin-derived peptide displays anti-angiogenic activity and inhibits tumour-induced and retinal neovascularization","volume":"165","author":"GM Palmer","year":"2012","journal-title":"Br J Pharmacol"},{"key":"ref28","doi-asserted-by":"crossref","first-page":"598","DOI":"10.1111\/j.1549-8719.2011.00120.x","article-title":"A human neutralizing antibody specific to Ang-2 inhibits ocular angiogenesis","volume":"18","author":"ES Rennel","year":"2011","journal-title":"Microcirculation"}],"updated-by":[{"DOI":"10.1371\/journal.pone.0097979","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2014,5,12]],"date-time":"2014-05-12T00:00:00Z","timestamp":1399852800000}}],"container-title":["PLoS ONE"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/dx.plos.org\/10.1371\/journal.pone.0090009","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,8,7]],"date-time":"2019-08-07T22:21:01Z","timestamp":1565216461000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0090009"}},"subtitle":[],"editor":[{"given":"Anthony W. I.","family":"Lo","sequence":"first","affiliation":[]}],"short-title":[],"issued":{"date-parts":[[2014,2,28]]},"references-count":28,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2014,2,28]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0090009","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,2,28]]}}}